Publication | Open Access
A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)
21
Citations
33
References
2016
Year
Tumor BiologySurgical OncologyPancreatic CancerPancreatic Neuroendocrine TumorPancreatic Fluid CollectionMedicineSurgical PathologyImmunologyPrognosisPathologyCancer GenomicsPhlda-3 Ihc ExpressionMethylation AnalysisNeuroendocrine TumorsMolecular DiagnosticsOncologyRadiation OncologyCancer Research
Pancreatic neuroendocrine tumor (PanNET) is a neoplastic entity in which few prognostic factors are well-known. Here, we aimed to evaluate the prognostic significance of N-myc downstream-regulated gen-1 (NDRG-1), O6-methylguanine DNA methyltransferase (MGMT) and Pleckstrin homology-like domain family A member 3 (PHLDA-3) by immunohistochemistry (IHC) and methylation analysis in 92 patients with resected PanNET and follow-up longer than 24 months. In multivariate analyses, ki-67 and our immunohistochemistry prognostic score (IPS-based on MGMT, NDRG-1 and PHLDA-3 IHC expression) were independent prognostic factors for disease-free-survival (DFS), while age and IPS were independent prognostic factors for overall survival (OS). Our IPS could be a useful prognostic biomarker for recurrence and survival in patients following resection for PanNET.
| Year | Citations | |
|---|---|---|
Page 1
Page 1